View Older Stories View More Recent Stories

Jul 30, 2020 09:48AM AstraZeneca (AZN) Announces TAGRISSO Granted Breakthrough Therapy Designation in the US for Adjuvant Treatment of Patients With Stage IB-IIIA EGFR-mutated Lung Cancer
Jul 30, 2020 09:47AM TAGRISSO Granted Breakthrough Therapy Designation in the US for the Adjuvant Treatment of Patients With Stage IB-IIIA EGFR-mutated Lung Cancer
Jul 28, 2020 07:21AM AstraZeneca (AZN) Announces FARXIGA Met All Primary and Secondary Endpoints in Groundbreaking Phase III DAPA-CKD Trial for Treatment of Patients With CKD
Jul 28, 2020 07:00AM FARXIGA Met All Primary and Secondary Endpoints in Groundbreaking Phase III DAPA-CKD Trial for the Treatment of Patients With Chronic Kidney Disease
Jul 27, 2020 06:33AM Emergent BioSolutions (EBS) Reports Agreement to AstraZeneca (AZN) to Expand Manufacturing for COVID-19 Vaccine Candidate
Jul 24, 2020 08:10AM BREZTRI AEROSPHERE approved in the US for the maintenance treatment of COPD
Jul 20, 2020 10:11AM Oxford/AstraZeneca (AZN) vaccine data looks 'mediocre' - STAT's Feuerstein
Jul 16, 2020 08:16AM AstraZeneca (AZN) Announces FARXIGA Granted Fast Track Designation in US for Heart Failure Following MI Leveraging an Innovative Registry-Based Trial Design
Jul 16, 2020 08:12AM FARXIGA Granted Fast Track Designation in the US for Heart Failure Following Acute Myocardial Infarction Leveraging an Innovative Registry-Based Trial Design
Jul 16, 2020 07:05AM AstraZeneca (AZN) Announces BRILINTA Significantly Reduced Rate of Composite of Stroke and Death in Patients Who Had an Acute Ischemic Stroke or TIA in Phase III THALES Trial
Jul 16, 2020 07:00AM BRILINTA Significantly Reduced the Rate of the Composite of Stroke and Death in Patients Who Had an Acute Ischemic Stroke or Transient Ischemic Attack in the Phase III THALES Trial
Jul 15, 2020 07:30AM Bob Harper and AstraZeneca Bring Virtual Series to Heart Attack Survivors to Inspire Others with Stories About Second Chances
Jul 9, 2020 07:02AM AstraZeneca (AZN) Reports BRILINTA Granted FDA Priority Review
Jul 9, 2020 07:00AM BRILINTA Granted FDA Priority Review for the Reduction of Subsequent Stroke in Patients Who Had an Acute Ischemic Stroke or Transient Ischemic Attack
Jul 8, 2020 06:56AM AstraZeneca (AZN), Merck (MRK) Announce LYNPARZA Approved in EU for Germline BRCA-mutated Metastatic Pancreatic Cancer
Jun 24, 2020 02:49PM AstraZeneca (AZN) Reports PT010 Significantly Reduced Rate of Moderate or Severe COPD Exacerbations in Phase III ETHOS Trial
Jun 24, 2020 02:48PM PT010 Significantly Reduced Rate of Moderate or Severe COPD Exacerbations in Phase III ETHOS Trial
Jun 11, 2020 08:48AM Emergent BioSolutions (EBS) Announces Pact to be U.S. Manufacturing Partner for AstraZeneca's (AZN) COVID-19 Vaccine Candidate
Jun 11, 2020 07:01AM AstraZeneca to Showcase Leadership in Treating Type 2 Diabetes and Cardiorenal Complications at ADA 2020
Jun 1, 2020 07:02AM AstraZeneca (AZN) BRILINTA Approved in US to Reduce Risk of First Heart Attack or Stroke in High-Risk Patients with CAD
Jun 1, 2020 07:00AM BRILINTA Approved in the US to Reduce the Risk of a First Heart Attack or Stroke in High-Risk Patients with Coronary Artery Disease
May 29, 2020 08:09AM AstraZeneca (AZN) Reports ENHERTU (fam-trastuzumab deruxtecan-nxki) Demonstrated Meaningful Clinical Activity in Patients w/ HER2-mutant NSCLC in Interim Analysis of Ph. 2 DESTINY-Lung01 Trial
May 29, 2020 08:05AM AstraZeneca (AZN) Reports IMFINZI (durvalumab) Showed Sustained OS Benefit in 1st-Line Extensive-Stage SCLC in Ph. 3 CASPIAN Trial
May 29, 2020 08:01AM IMFINZI plus tremelimumab Demonstrated Promising Clinical Activity and Tolerability in Patients With Advanced Liver Cancer
May 29, 2020 08:01AM IMFINZI® (durvalumab) Showed a Sustained Overall Survival Benefit in 1st-Line Extensive-Stage Small Cell Lung Cancer in the Phase III CASPIAN Trial
May 29, 2020 08:00AM ENHERTU (fam-trastuzumab deruxtecan-nxki) Demonstrated Meaningful Clinical Activity in Patients With HER2-mutant Non-small Cell Lung Cancer in Interim Analysis of Phase II DESTINY-Lung01 Trial
May 29, 2020 08:00AM ENHERTU (fam-trastuzumab deruxtecan-nxki) Significantly Improved Tumor Response Rate and Overall Survival in HER2-positive Metastatic Gastric Cancer in Phase II DESTINY-Gastric01 Trial
May 29, 2020 08:00AM ENHERTU (fam-trastuzumab deruxtecan-nxki) Achieved a Tumor Response Rate of 45.3% in Patients With HER2-Positive Metastatic Colorectal Cancer in Phase II DESTINY-CRC01
May 28, 2020 05:01PM AstraZeneca (AZN) Announces TAGRISSO Demonstrated Unprecedented Patient Benefit in the Adjuvant Treatment of EGFR-Mutated Lung Cancer
May 28, 2020 05:00PM TAGRISSO Demonstrated Unprecedented Patient Benefit in the Adjuvant Treatment of EGFR-Mutated Lung Cancer
May 20, 2020 07:04AM Foundation Medicine Receives FDA Approval for FoundationOne®CDx as the Companion Diagnostic for LYNPARZA® to Identify Patients with HRR-Mutated Metastatic Castration-Resistant Prostate Cancer
May 20, 2020 07:00AM LYNPARZA® (Olaparib) Approved in the US for HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer
May 20, 2020 06:57AM Merck (MRK), AstraZeneca (AZN) Report LYNPARZA (olaparib) Approved by FDA for Treatment of HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer
May 18, 2020 07:00AM ENHERTU Granted Breakthrough Therapy Designation in the US for HER2-Mutant Metastatic Non-Small Cell Lung Cancer
May 13, 2020 05:01PM AstraZeneca Advances the Science of Cancer Medicine With Practice-Changing Data at the ASCO20 Virtual Scientific Program
May 11, 2020 07:24AM UPDATE: AstraZeneca (AZN), Daiichi Sankyo Co. Report ENHERTU Granted Breakthrough Therapy Designation in US for HER2-Positive Metastatic Gastric Cancer
May 11, 2020 07:05AM ENHERTU Granted Breakthrough Therapy Designation in the US for HER2-Positive Metastatic Gastric Cancer
May 11, 2020 07:00AM LYNPARZA (Olaparib) Approved in US as 1st-line Maintenance Treatment With bevacizumab For HRD-Positive Advanced Ovarian Cancer
May 6, 2020 07:18AM AstraZeneca (AZN) Announces FARXIGA Approved in US for Treatment of Heart Failure in Patients With Heart Failure With Reduced Ejection Fraction
May 6, 2020 07:00AM FARXIGA Approved in the US for the Treatment of Heart Failure in Patients With Heart Failure With Reduced Ejection Fraction
Apr 27, 2020 07:00AM LOKELMA US Label Updated to Include Dosing Guidance for the Treatment of Hyperkalemia in Patients With End-Stage Renal Disease on Hemodialysis
Apr 24, 2020 06:55AM LYNPARZA® (Olaparib) Demonstrated Overall Survival Benefit in Phase III PROfound Trial for BRCA1/2 or ATM-Mutated Metastatic Castration-Resistant Prostate Cancer
Apr 13, 2020 06:57AM AstraZeneca (AZN), Merck (MRK) Announce KOSELUGO Approved by FDA for Pediatric Patients Two Years and Older With NF1 and Symptomatic, Inoperable PN
Apr 13, 2020 06:55AM KOSELUGO™ (selumetinib) Approved In US For Pediatric Patients With Neurofibromatosis Type 1 Plexiform Neurofibromas
Mar 30, 2020 09:18AM AstraZeneca (AZN) announces BRILINTA reduced bleeding vs dual therapy in high-risk coronary patients in sub-analyses from Phase IV TWILIGHT trial
Mar 30, 2020 09:16AM BRILINTA reduced bleeding vs dual therapy in high-risk coronary patients in sub-analyses from Phase IV TWILIGHT trial
Mar 30, 2020 07:09AM AstraZeneca (AZN) Announces FARXIGA Phase III DAPA-CKD Trial Will Be Stopped Early After Overwhelming Efficacy in Patients With CKD
Mar 30, 2020 07:05AM FARXIGA Phase III DAPA-CKD Trial Will Be Stopped Early After Overwhelming Efficacy in Patients With Chronic Kidney Disease
Mar 30, 2020 07:02AM AstraZeneca (AZN) Announces IMFINZI Approved in US for Extensive-Stage Small Cell Lung Cancer
Mar 30, 2020 07:00AM IMFINZI (durvalumab) Approved in the US for Extensive-Stage Small Cell Lung Cancer
View More Recent Stories View Older Stories